Semaglutide
Ozempic · Wegovy · Rybelsus
The weight loss drug that changed everything. FDA-approved, clinically proven, and genuinely revolutionary.
What is Semaglutide?
Semaglutide isn't some underground biohacking compound — it's a legitimate, FDA-approved medication that has fundamentally changed how medicine thinks about obesity. Originally developed for Type 2 diabetes (Ozempic), researchers noticed patients were losing significant weight as a side effect. Novo Nordisk then developed Wegovy specifically for weight management, and the results have been extraordinary.
The numbers speak for themselves: in the STEP trials, patients on Wegovy lost an average of 14.9% of their body weight over 68 weeks. That's not a crash diet — that's a sustained, clinically meaningful reduction that improves cardiovascular risk, blood pressure, and metabolic health. Nothing else in the history of weight loss medication has come close.
How Does It Work?
Semaglutide mimics GLP-1 (glucagon-like peptide-1), a hormone your gut produces after eating. GLP-1 tells your brain you're full, slows gastric emptying (so food stays in your stomach longer), and improves insulin sensitivity. Semaglutide is a modified version of GLP-1 that lasts much longer in the body — you only inject once weekly.
The appetite suppression is profound. Patients consistently report that food simply becomes less interesting. The constant background noise of hunger and cravings goes quiet. This isn't willpower — it's biochemistry.
What Does The Research Say?
Strong clinical evidence from human trials.
Semaglutide has some of the strongest clinical evidence of any weight loss intervention ever studied. The STEP trials (1-5) consistently showed 12-17% body weight reduction. The SELECT trial showed a 20% reduction in major cardiovascular events. This is a drug that doesn't just help you lose weight — it reduces your risk of heart attack and stroke.
Ongoing research is exploring benefits beyond weight loss: potential neuroprotective effects (Alzheimer's trials underway), anti-inflammatory properties, NAFLD improvement, and kidney protection.
Reported Dosages
These are dosages reported in research literature and community reports. They are NOT medical recommendations. Always consult a healthcare professional.
Prescription only. Must be prescribed by a doctor.
Ozempic (diabetes): 0.25mg → 0.5mg → 1mg → 2mg weekly escalation.
Wegovy (weight loss): 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg weekly escalation over 16 weeks.
Rybelsus (oral): 3mg → 7mg → 14mg daily.
Do NOT use without medical supervision. Dosage must be titrated slowly.
Side Effects & Risks
Common: nausea (especially during dose escalation), vomiting, diarrhea, constipation. These usually improve over time. Rare but serious: pancreatitis, gallbladder issues, thyroid tumours (observed in rodent studies — unclear in humans, but contraindicated in people with personal/family history of medullary thyroid cancer). Loss of muscle mass is a concern — resistance training is strongly recommended alongside.
Legal Status by Country
Prescription only (NHS and private). Wegovy approved for weight management. Ozempic for diabetes.
Prescription only. FDA-approved. Covered by some insurance plans.
Prescription only. EMA-approved.
Prescription only. PBS-listed for diabetes. Weight management access varies.
Important Disclaimer
This profile is for educational and research purposes only. It does not constitute medical advice. Semaglutide may be regulated or illegal in your jurisdiction. Do not use any compound without consulting a qualified healthcare professional. StackPedia does not sell, supply, or promote the use of any controlled substance.